3'- deamino- 3'- (3- cyano- 4- morpholinyl)doxorubicin

more effective and has lower toxicity than doxorubicin

Also Known As:

3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin; 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin, (S-(8S-cis))-isomer; A 489; A-489; MRA-CN; cyanomorpholino doxorubicin; cyanomorpholinoadriamycin; 5,12-Naphthacenedione, 10-((3-(3-cyano-4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-

Networked: 23 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Biała, Ewa: 1 article (03/2022)
2.	Imiołczyk, Barbara: 1 article (03/2022)
3.	Kazimierczyk, Marek: 1 article (03/2022)
4.	Kurzyńska-Kokorniak, Anna: 1 article (03/2022)
5.	Ostrowski, Tomasz: 1 article (03/2022)
6.	Wojnicka, Marta: 1 article (03/2022)
7.	Wrzesinski, Jan: 1 article (03/2022)
8.	Żydowicz-Machtel, Paulina: 1 article (03/2022)
9.	Chen, Changqing: 1 article (12/2018)
10.	Guo, Zefeng: 1 article (12/2018)

Related Diseases

1.	Cardiotoxicity 05/04/1988 - "The favorable therapeutic ratio, the non-cross-resistance with DOX, and the previously described lack of cardiac toxicity all make MRA-CN an attractive candidate for clinical trials in patients with acute leukemia." 09/01/1991 - "In addition to dose related toxicity manifested as weight loss and effects on the haematology profile, we obtained evidence of cardiotoxicity with MRA-CN, which has not been reported previously. " 09/01/1987 - "Cyanomorpholinoadriamycin, an analogue which is 100 to 1000 times more potent than adriamycin (doxorubicin) as an antineoplastic agent, has been shown here and elsewhere to be equivalent to adriamycin in stimulating oxygen radical production by beef heart mitochondria and to produce similar cardiotoxicity at equimolar concentrations. " 10/21/1992 - "The doxorubicin analogues cyanomorpholino doxorubicin (MRA-CN) and morpholino doxorubicin (MRA) were synthesized in an attempt to avoid the cardiotoxicity and drug resistance of doxorubicin therapy. "
2.	Leukemia 05/04/1988 - "There was a lack of correlation between MRA-CN and DOX at a drug concentration at which the colony formation is inhibited by 50% in the leukemia cell lines (correlation coefficient = 0.38), which supported the previous reports of non-cross-resistance between these two agents. " 05/04/1988 - "In addition, the therapeutic ratio was uniformly greater than 1, indicating that each leukemia cell line tested was more sensitive than CFU-GM to MRA-CN in vitro. " 05/04/1988 - "MRA-CN was found to be 100 times more potent than DOX against normal myeloid progenitors--colony-forming units, granulocyte-macrophage (CFU-GM)--and 40-240 times more potent than DOX against leukemia cell lines. " 05/04/1988 - "The effect of MRA-CN on the leukemia cells was compared to its toxicity on normal myeloid progenitors (therapeutic ratio) and to the effect of DOX on the leukemia and normal cells. " 05/04/1988 - "The favorable therapeutic ratio, the non-cross-resistance with DOX, and the previously described lack of cardiac toxicity all make MRA-CN an attractive candidate for clinical trials in patients with acute leukemia."
3.	Neoplasms (Cancer) 01/01/2023 - "ANTECEDENTES:Aunque se reconoce cada vez más que el cáncer de colon del lado derecho tiene un peor pronóstico que el cáncer colorrectal del lado izquierdo para las metástasis hepáticas colorrectales, se sabe poco acerca de las diferencias entre el recto y el colon del lado izquierdo.OBJETIVO:Este estudio evaluó el valor pronóstico de la ubicación del tumor primario en pacientes con metástasis hepáticas colorrectales examinando el recto y el colon del lado izquierdo por separado.DISEÑO:Este fue un estudio retrospectivo de 2003 a 2017.ENTORNO CLÍNICO:El estudio se llevó a cabo en un Hospital del Centro Nacional de Cáncer.PACIENTES:La cohorte del estudio incluyó a 489 pacientes con metástasis hepáticas colorrectales de cáncer de colon del lado derecho (n = 119, 24%), cáncer de colon del lado izquierdo (n = 251, 51%) o cáncer de recto (n = 119, 24%). " 03/26/2022 - "The research model used here consisted of the following human renal cells: hESCs, HEK-293T, HK-2 and A-489 kidney tumor cells, which, together, mimic the different stages of kidney development. " 01/15/1994 - "Thus, MRA-CN induces apoptosis in L5178Y cells, and this effect may be important for the anti-tumor activity of this agent. " 09/01/1991 - "In view of the potential of MRA-CN in cancer treatment, these results need to be confirmed and extended." 12/01/2018 - "The synthesized GA-rGO nanomaterials exhibited a very good apoptosis and toxic effect on A-489 renal cancer cells, which was found to exhibit enhanced tumor cytotoxicity in RF combination treatment compared to RF treated alone. "
4.	Carcinoma (Carcinomatosis) 01/01/1992 - "We have developed an ovarian carcinoma cell line ES-2R that is 4-fold resistant to MRA-CN, compared to the parental ES-2 cells. " 10/01/1991 - "To further examine mechanisms of action and resistance to MRA-CN, a cell line resistant to MRA-CN, ES-2R, was established by growing a human ovarian carcinoma cell line, ES-2, in increasing concentrations of the drug. " 10/01/1991 - "Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin." 07/01/1990 - "A human ovarian carcinoma cell line, ES-2, was grown in increasing concentrations of MRA-CN from 0.1 to 0.5 nM. The resultant resistant subline, ES-2R, was 4-fold resistant to MRA-CN. " 08/01/1987 - "Cellular pharmacology of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin and structural analogues in human colon carcinoma HT-29 cells in vitro."
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/1995 - "The cytotoxic action of two morpholino anthracyclines, methoxymorpholino anthracycline (MRA-MT, FCE 23,762) and cyanomorpholino anthracycline (MRA-CN), was compared with the cytotoxicity of doxorubicin (DOX), the topoisomerase II inhibitor etoposide (VP-16), the topoisomerase I inhibitor camptothecin, methotrexate, and cisplatin in GLC4, a human small-cell lung-cancer cell line, in GLC4-Adr, its P-glycoprotein (Pgp)-negative, multidrug-resistant (MDR; 100-fold DOX-resistant) subline with overexpression of the MDR-associated protein (MRP) and a lowered topoisomerase II activity, and in GLC4-CDDP, its cisplatin-resistant subline. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	DNA (Deoxyribonucleic Acid)
3.	3'- deamino- 3'- (3- cyano- 4- morpholinyl)doxorubicin
4.	Anthracyclines
5.	Morpholinos
6.	Anti-Bacterial Agents (Antibiotics)
7.	3'- (4- morpholinyl)- 3'- deaminodaunorubicin
8.	Topoisomerase II Inhibitors
9.	Topoisomerase I Inhibitors
10.	Member 1 Subfamily B ATP Binding Cassette Transporter

Related Therapies and Procedures

1.	Therapeutics